Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Spiramycin adipate is the adipate salt of spiramycin, a 16-membered macrolide antibiotic produced by *Streptomyces ambofaciens*. It exerts its antibacterial effect by binding to the 50S subunit of the bacterial ribosome, specifically the 23S rRNA, which inhibits protein synthesis by blocking the translocation step. Spiramycin has a broad spectrum of activity against Gram-positive bacteria, certain Gram-negative bacteria, and *Mycoplasma* species, and is also effective against the protozoan *Toxoplasma gondii*. While spiramycin is used in human medicine for respiratory infections and toxoplasmosis, the adipate salt is predominantly utilized in veterinary medicine for treating infections in livestock and poultry. Wuxi Fortune Pharmaceutical manufactures spiramycin adipate as an active pharmaceutical ingredient (API).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spiramycin adipate.